Granted Patent
B2
US 12,697,368 · App. 17/597,802 · Granted Aug 4, 2026
TSG6 polypeptide fragment for dry eye disease
Assignee:
THE UNIVERSITY OF MANCHESTER
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein is a treatment of dry eye disease and particularly, although not exclusively, to the treatment of dry eye disease with a LINK_TSG6 polypeptide.
Claims (14)
1 . A method for treating dry eye disease (DED) in a subject, comprising administering topically to the subject one or more eye drops, wherein the one or more eye drops comprise an effective amount of a polypeptide comprising a Link module from Tumour necrosis factor-stimulated gene 6 (LINK_TSG6),
wherein the LINK_TSG6 consists of (i) the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 9, or (ii) the amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 7 or 9 and up to 100 amino acids in length; and
wherein the treating comprises healing of a corneal epithelial defect, and wherein healing of the corneal epithelial defect is determined by a decrease in ocular staining score as compared to (i) the subject prior to the administering or (ii) an untreated control.
2 . The method according to claim 1 , wherein the method provides one or more effects selected from the group consisting of:
an increase in tear production;
suppression of inflammation; and
a higher number of conjunctival goblet cells.
3 . The method according to claim 1 , wherein the method comprises administering the one or more eye drops two times per day.
4 . The method according to claim 1 , wherein the method comprises administering the one or more eye drops less than four times per day.
5 . The method according to claim 1 , wherein the method further comprises co-administration with one or more of prednisolone, cyclosporine, Lifitegrast or artificial tears.
6 . The method according to claim 1 , wherein the method comprises administering to the subject the one or more eye drops comprising about 10-200 μg of the polypeptide per eye.
7 . The method according to claim 2 , wherein the suppression of inflammation comprises a decrease in production of one or more pro-inflammatory cytokines in the subject's cornea or intraorbital lacrimal glands; wherein the pro-inflammatory cytokines are optionally selected from TNF-α, IL-6, IFN-γ and IL-1β.
8 . The method according to claim 1 , wherein the subject has Sjögren's syndrome.
9 . The method according to claim 6 , wherein the method comprises administering to the subject the one or more eye drops comprising 120-150 μg of the polypeptide per eye.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 9, 2023
From: SEOUL NATIONAL UNIVERSITY HOSPITAL
To: THE UNIVERSITY OF MANCHESTER
Reel/Frame 063910/0642 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 2, 2023
From: OH, JOO YOUN
To: SEOUL NATIONAL UNIVERSITY HOSPITAL
Reel/Frame 062856/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 2, 2023
From: DAY, ANTHONY; MILNER, CAROLINE
To: THE UNIVERSITY OF MANCHESTER
Reel/Frame 062916/0609 →
Priority Claims (1)
GB 1910645
· Jul 25, 2019
· national
Continuity (1)
Related Publication
20220288161A1
· Sep 15, 2022
References Cited (75)
US 9062103B2
· Prockop et al.
· 2015
[cited by applicant]
US 9878003B2
· Day et al.
· 2018
[cited by applicant]
US 20030023406A1
· Kataoka
· 2003
[cited by applicant]
US 20160075750A1
· Prockop et al.
· 2016
[cited by applicant]
US 20160297854A1
· Ghosh et al.
· 2016
[cited by applicant]
US 20170291939A1
· Di Padova et al.
· 2017
[cited by applicant]
US 20200038521A1
· Trippel et al.
· 2020
[cited by applicant]
US 20200103418A1
· Hackney et al.
· 2020
[cited by applicant]
US 20250121028A1
· Day et al.
· 2025
[cited by applicant]
CN 104995303A
· 2015
[cited by applicant]
EP 2001499B1
· 2013
[cited by applicant]
WO 2007101988A2
· 2007
[cited by applicant]
WO 2011139357A1
· 2011
[cited by applicant]
WO 2013067133A1
· 2013
[cited by applicant]
WO 2015084706A1
· 2015
[cited by applicant]
WO 2015094846A2
· 2015
[cited by applicant]
WO 2018165218A1
· 2018
[cited by applicant]
WO 2021013452A1
· 2021
[cited by applicant]
WO 2022157181A1
· 2022
[cited by applicant]
Lin et al., “dry eye disease: review of diagnostic approaches and treatments,” Saudi Journal of ophthalmology 28:173-181 (2014) (Year: 2014).
[cited by examiner]
Introduction to Corneal Disorders, Merck manuals, accessed Sep. 20, 2021 at URL merckmanuals.com/professional/eye-disorders/corneal-disorders/introduction-to-corneal-disorders?query=corneal disorders (Year: 2021).
[cited by examiner]
Corneal Ulcer, Merck manuals, accessed Sep. 2021 at URL merckmanuals.com/professional/eye-disorders/corneal-disorders/corneal-ulcer (Year: 2021).
[cited by examiner]
Keratoconus, Merck manuals, accessed Sep. 20, 2021 at URL merckmanuals.com/professional/eye-disorders/corneal-disorders/keratoconus (Year: 2021).
[cited by examiner]
Corneal dystrophies, accessed Jan. 2, 2025 at URL nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/corneal-conditions/corneal-dystrophies (Year: 2025).
[cited by examiner]
Drumm et al, Genetic Variation and Clinical Heterogeneity in Cystic Fibrosis, Annu. Rev. Pathol. Mech. Dis., 2012, 7, pp. 267-282 (Year: 2012).
[cited by examiner]
Yampolsky et al, The Exchangeability of Amino Acids in Proteins, Genetics, 2005, 170, pp. 1459-1472. (Year: 2005).
[cited by examiner]
Thia et al, “New developments in the management of persistent corneal epithelial defects,” Survey Opthalmol. 68:1093-1114 (2023) (Year: 2023).
[cited by examiner]
International Search Report and Written Opinion for International Application No. PCT/EP2020/067448, entitled “TSG6 Polypeptide Fragment for Dry Eye Disease,” consisting of 14 pages. Date of Mailing: Sep. 23, 2020.
[cited by applicant]
Day, et al., “TSG-6: A Multifunctional Protein with Anti-Inflammatory and Tissue-Protective Properties,” Matrix Biol. 78-79, 60-83 (2019).
[cited by applicant]
Kim et al., “Comparison of Topical Application of TSG-6, Cyclosporine, and Prednisolone for Treating Dry Eye,” Cornea, 35:536-542 (2016).
[cited by applicant]
Ghosh et al., “Long acting protein drugs for the treatment of ocular diseases,” Nature Communications, pp. 1-15 (2017).
[cited by applicant]
Day, A.J. et al., “TSG-6: A Multifunctional Protein with Anti-Inflammatory and Tissue-Protective Properties,” Matrix Biol. 78-79: 60-83 (2018).
[cited by applicant]
Day, J et al: “A novel chondroprotective property of TSG-6 has therapeutic potential for OA.” Osteoarthritis and Cartilage vol. 24 (Apr. 1, 2016).
[cited by applicant]
Emami, A. et al., “Toxicology Evaluation of Drugs Administered via Uncommon Routes: Intranasal, Intraocular, Intrathecal/Intraspinal and Intra-Articular,” Int J Toxicol, 37(1): 4-27 (2018).
[cited by applicant]
Ghosh, J.G. et al., “Long acting protein drugs for the treatment of ocular diseases,” Nature Communications, pp. 1-15 (2017).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2022/051101, entitled “Use of Link-TSG6 for the Treatment of Osteoarthritic Pain,” consisting of 10 pages. Date of Mailing: Apr. 28…
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/EP22/051101, mailed on Apr. 28, 2022, 10 pages.
[cited by applicant]
Kim, Y.J. et al., “Comparison of Topical Application of TSG-6, Cyclosporine, and Prednisolone for Treating Dry Eye,” Cornea, 35:536-542 (2016).
[cited by applicant]
Kotwal, N. et al., Quantitative Analysis of Mouse Articular Cartilage using Equilibrium Partitioning of Ionic Contrast Agent via Micro Computed Tomography (EPIC-uCT), ORS 2011 Annual Meeting, Paper No. 214, 1 page (2011…
[cited by applicant]
Ichiseki, T. et al., “Intraarticularly-Injected Mesenchymal Stem Cells Stimulate Anti-Inflammatory Molecules and Inhibit Pain Related Protein and Chondrolytic Enzymes in a Monoiodoacetate-Induced Rat Arthritis Model,” I…
[cited by applicant]
Wehr, B. et al., “Tibial Cartilage Surface Area, Thickness and Volume in Various Animal Species and in Humans,” Osteoarthritis and Cartilage, vol. 15, abstract, 2 pages (No Date Given).
[cited by applicant]
Yang, H. et al., “Anti-inflammatory protein TSG-6 secreted by bone marrow mesenchymal stem cells attenuates neuropathic pain by inhibiting the TLR2/MyD88/NF-kB signaling pathway in spinal microglia,” Journal of Neuroinf…
[cited by applicant]
Bo-Li Zhang et al., Common general knowledge: Guidelines for Rational Clinical Use of Chinese Patent Medicines in Common Diseases: Opthalmology, Jul. 31, 2015, Huaxia Publishing House.
[cited by applicant]
Fu et al. “Osteoarthritis: the genesis of pain”, Rheumatology, vol. 57, No. suppl_4, Dec. 15, 2017 (Dec. 15, 2017), pp. iv43-iv50, XP093248341, ISSN: 1462-0324, DOI: 10.1093/rheumatology/kex419.
[cited by applicant]
Joo Youn Oh, et al., The Link module of human TSG-6 (Link_TSG6) promotes wound healing, suppresses inflammation and improves glandular function in mouse models of Dry Eye Disease, The Ocular Surface (2022), 40-50, 24.
[cited by applicant]
Altschul et al., “Basic Local Alignment Search Tool”, J. Mol. Biol., vol. 215, 1990, pp. 403-410.
[cited by applicant]
Baranova et al., “The Inflammation-associated Protein TSG-6 Cross-links Hyaluronan via Hyaluronan-induced TSG-6 Oligomers”, The Journal of Biological Chemistry, vol. 286, No. 29, Jul. 22, 2011, pp. 25675-25686.
[cited by applicant]
Blundell et al., “The Link Module from Ovulation- and Inflammation-associated Protein TSG-6 Changes Conformation on Hyaluronan Binding*s”, The Journal of Biological Chemistry, vol. 278, No. 49, Dec. 5, 2003, pp. 49261-4…
[cited by applicant]
Devereux et al., “A comprehensive set of sequence analysis programs for the VAX”, Nucleic Acids Research, vol. 12, No. 1, 1984, pp. 387-395.
[cited by applicant]
Dyer et al., “The Anti-inflammatory Protein TSG-6 Regulates Chemokine Function by Inhibiting Chemokine/Glycosaminoglycan Interactions*”, The Journal of Biological Chemistry, vol. 291, No. 24, Jun. 10, 2016, pp. 12627-12…
[cited by applicant]
Dyer et al., “TSG-6 inhibits neutrophil migration via direct interaction with the chemokine CXCL8”, J. Immunol., vol. 192, No. 5, Mar. 1, 2014, pp. 2177-2185.
[cited by applicant]
Getting et al., “The Link Module from Human TSG-6 Inhibits Neutrophil Migration in a Hyaluronan- and Inter- -inhibitor-independent Manner*”, The Journal of Biological Chemistry, vol. 277, No. 52, Dec. 27, 2002, pp. 5106…
[cited by applicant]
Henikoff et al., “Amino acid substitution matrices from protein blocks”, Proc. Natl. Acad. Sci., vol. 89, Nov. 1992, pp. 10915-10919.
[cited by applicant]
Karlin et al., “Applications and statistics for multiple high-scoring segments in molecular sequences”, Proc. Natl. Acad. Sci., vol. 90, Jun. 1993, pp. 5873-5877.
[cited by applicant]
Kuznetsova et al., “The N-terminal Module of Thrombospondin-1 Interacts with the Link Domain of TSG-6 and Enhances its Covalent Association with the Heavy Chains of Inter- -trypsin Inhibitor*”, The Journal of Biological…
[cited by applicant]
Mahoney et al., “Characterization of the Interaction between Tumor Necrosis Factor-stimulated Gene-6 and Heparin”, The Journal of Biological Chemistry, vol. 280, No. 29, Jul. 22, 2005, pp. 27044-27055.
[cited by applicant]
Mahoney et al., “Mapping the Hyaluronan-binding Site on the Link Module from Human Tumor Necrosis Factor-stimulated Gene-6 by Site-directed Mutagenesis”, The Journal of Biological Chemistry, vol. 276, No. 25, Jun. 22, 2…
[cited by applicant]
Mahoney et al., “TSG-6 Regulates Bone Remodeling through Inhibition of Osteoblastogenesis and Osteoclast Activations”, The Journal of Biological Chemistry vol. 283, No. 38, Sep. 19, 2008, pp. 25952-25962.
[cited by applicant]
Nentwich et al., “A Novel Allelic Variant of the Human TSG-6 Gene Encoding an Amino Acid Difference in the CUB Module”, The Journal of Biological Chemistry, vol. 277, No. 18, May 3, 2002, pp. 15354-15362.
[cited by applicant]
Parkar et al., “Overlapping sites on the Link module of human TSG-6 mediate binding to hyaluronan and chondroitin-4-sulphate”, FEBS Letters, vol. 410, No. 2-3, Jun. 30, 1997, pp. 413-417.
[cited by applicant]
Parkar et al., “TSG-6 interacts with hyaluronan and aggrecan in a pH-dependent manner via a common functional element: implications for its regulation in in£amed cartilage”, FEBS Letters, vol. 428, 1998, pp. 171-176.
[cited by applicant]
Salustri et al., “PTX3 plays a key role in the organization of the cumulus oophrus extracellular matrix and in in vivo fertilization”, Development, vol. 131, No. 9, 2004, pp. 1577-1586.
[cited by applicant]
Stephen F. Altschul, “A Protein Alignment Scoring System Sensitive at All Evolutionary Distances”, J. Mol. Evol., vol. 36, 1993, pp. 290-300.
[cited by applicant]
Akpek EK, Sheppard JD, Krösser S. Corneal Staining Responder Analysis: A Clinically Meaningful Dry Eye Outcome. Ophthalmology. Dec. 2025; 132(12):1335-1341. doi: 10.1016/j.ophtha.2025.07.015. Epub Jul. 24, 2025. PMID: 4…
[cited by applicant]
Aragona P, et al. Modern approach to the treatment of dry eye, a complex multifactorial disease: a P.I.C.A.S.S.O. board review. Br J Ophthalmol. Apr. 2021;105(4):446-453. doi: 10.1136/bjophthalmol-2019-315747. Epub Jul.…
[cited by applicant]
Oh, J.Y. et al., “Anti-inflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injury,” PNAS, vol. 107; No. 39; 16875-16880 (2010).
[cited by applicant]
Sheppard JD, Torkildsen GL, Lonsdale JD, D'Ambrosio FA Jr, McLaurin EB, Eiferman RA, Kennedy KS, Semba CP; OPUS-1 Study Group. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1…
[cited by applicant]
Taloni A, Coco G, Pellegrini M, Scorcia V, Giannaccare G. Efficacy of Perfluorohexyloctane for the Treatment of Patients with Dry Eye Disease: A Meta-Analysis. Ophthalmic Res. 2025;68(1):41-51. doi: 10.1159/000542149. E…
[cited by applicant]
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Dry Eye: Developing Drugs for Treatment—Guidance for Industry (Draft Guidance). Dec. 2020.
[cited by applicant]
Curtis (Osteoarthritis Symptoms and Signs, Nov. 12, 2020) (Year: 2020).
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 18/262,113, mailed on Jan. 16, 2026, 23 pages.
[cited by applicant]
Final Office Action received for U.S. Appl. No. 18/262,113, mailed on May 6, 2026, 22 pages.
[cited by applicant]